Department of Medicine, Division of Gastroenterology and Hepatology, Medical University of South Carolina, 30 Courtenay Drive, Suite 249, MSC 702, Charleston, SC, 29425-2900, USA.
Alexandria Faculty of Medicine, Alexandria, Egypt.
Dig Dis Sci. 2019 Aug;64(8):2214-2218. doi: 10.1007/s10620-019-05523-8. Epub 2019 Feb 15.
Due to its smooth muscle relaxing properties, peppermint oil (PO) may relieve dysphagia and chest pain due to esophageal motility disorders.
To explore the impact of PO on dysphagia and/or chest pain in patients referred for motility testing.
Patients initiated on PO for dysphagia and/or chest pain from 2013 to 2016 were identified. We excluded patients with obstructing esophageal lesions, patients lost to follow-up, and those with preexisting cardiac conditions. Concentrated PO was given as commercially available dissolvable peppermint tablets; two tablets before meals were prescribed to patients with dysphagia and on an as-needed basis for patients with chest pain. Patient-reported symptom response was assessed using a modified five-point Likert scale.
Thirty-eight patients were included. Twenty-four patients (63%) reported improvement; 12 were much better and 12 were slightly better. Fourteen experienced no change and none reported feeling worse. Based on pre-treatment HRM, patients with distal esophageal spasm (DES) (n = 10) and esophagogastric junction outflow obstruction (EGJOO) (n = 8) appeared to demonstrate the best subjective improvement (83% and 100%, respectively) (P < 0.05).
PO appears to provide symptomatic relief in some patients with dysphagia and CP. Presence of a well-defined manometric disorder, particularly DES or EGJOO, appeared to predict response.
由于其平滑肌松弛特性，薄荷油（PO）可能缓解因食管动力障碍引起的吞咽困难和胸痛。
探讨 PO 对因动力障碍而接受检查的患者吞咽困难和/或胸痛的影响。
确定 2013 年至 2016 年因吞咽困难和/或胸痛开始使用 PO 的患者。我们排除了有食管阻塞性病变、失访患者和有预先存在的心脏疾病的患者。浓缩 PO 作为市售的可溶解薄荷片给予；吞咽困难的患者每餐服用两片，胸痛的患者按需服用。使用改良的五分制 Likert 量表评估患者报告的症状缓解情况。
共纳入 38 例患者。24 例（63%）患者报告症状改善；12 例明显改善，12 例略有改善。14 例无变化，无患者感觉恶化。根据治疗前 HRM，远端食管痉挛（DES）（n=10）和食管胃结合部流出梗阻（EGJOO）（n=8）患者的主观改善似乎最佳（分别为 83%和 100%）（P<0.05）。
PO 似乎可缓解一些吞咽困难和 CP 患者的症状。存在明确的动力障碍，特别是 DES 或 EGJOO，似乎可以预测反应。
